Amundi
BPMC

Amundi’s Blueprint Medicines BPMC Stock Holding History

Amundi’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8
Closed -$697 – 1728
2025
Q1 		$697 Buy
+8
New +$780 ﹤0.01% 2097
2022
Q4 		– Sell
-1,948
Closed -$127K – 1909
2022
Q3 		$127K Hold
1,948
– – ﹤0.01% 1521
2022
Q2 		$102K Hold
1,948
– – ﹤0.01% 1442
2022
Q1 		$133K Hold
1,948
– – ﹤0.01% 1430
2021
Q4 		$148K Hold
1,948
– – ﹤0.01% 1520
2021
Q3 		$200K Hold
1,948
– – ﹤0.01% 1440
2021
Q2 		$171K Buy
+1,948
New +$178K ﹤0.01% 1411

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Amundi's BPMC Position: Q2 2025 in Review

Amundi sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 8 shares — an estimated $697 sold.

Amundi first reported a position in BPMC in Q2 2021 and held it in 7 quarters. The position peaked at $200K in Q3 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Amundi reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 8 Blueprint Medicines shares in Q2 2025, an estimated $697.
  • Amundi first reported a position in Blueprint Medicines in Q2 2021 and held it in 7 quarters.
  • Amundi's Blueprint Medicines position peaked at $200K in Q3 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.